Endogenic regulation of proliferation and zinc transporters by pigment epithelial cells nonvirally transfected with PEDF

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5400-5407

  Johnen, Sandra ^a   Kazanskaya, Olga ^a   Armogan, Narendra ^b   Stickelmann, Christiane ^a   Stöcker, Michael ^c   Walter, Peter ^a   Thumann, Gabriele ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN ZO1; RETINOID BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ZINC TRANSPORTER; ZIP2 PROTEIN; ZNT3 PROTEIN; 11 CIS RETINAL BINDING PROTEIN; 11-CIS-RETINAL-BINDING PROTEIN; CARRIER PROTEIN; CATION TRANSPORT PROTEIN; EYE PROTEIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; SLC30A3 PROTEIN, HUMAN; SLC39A2 PROTEIN, HUMAN; ZINC;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; ELECTROPORATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHYSIOLOGY; PLASMID;

ANIMALS; BLOTTING, WESTERN; CARRIER PROTEINS; CATION TRANSPORT PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; NERVE GROWTH FACTORS; PLASMIDS; RABBITS; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERPINS; TRANSFECTION; ZINC;

EID: 80052810206     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6178     Document Type: Article

References (46)

1. Khandhadia S, Lotery A. Oxidation and age-related macular degeneration: insights from molecular biology. Expert Rev Mol Med. 2010;12:e34.
2. Zhou J, Cai B, Jang YP, Pachydaki S, Schmidt AM, Sparrow JR. Mechanisms for the induction of HNE-MDA-and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res. 2005;80:567-580.
3. Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol. 2002;240:996-1002.
4. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
5. Yamagishi S, Matsui T, Inoue H. Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp Clin Res. 2005;31:227-232.
6. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
7. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
8. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008;115:1039-1045.
9. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration-twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2005;112:1035-1047.
10. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular agerelated macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256.
11. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915-930.
12. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with antivascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev. 2009;4:CD007419.
13. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol. 2010;149:458e1-464. e1.
14. Dunavoelgyi R, Zehetmayer M, Simader C, Schmidt-Erfurth U. Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. Clin Exp Ophthalmol. 2007;35:878-880.
15. Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol. 2009;3:685-688.
16. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26:105-110.
17. Krishnan R, Goverdhan S, Lochhead J. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin Exp Ophthalmol. 2009;37:384-388.
18. Baeteman C, Hoffart L, Galland F, Ridings B, Conrath J. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study]. J Fr Ophtalmol. 2009;32:309-313.
19. Klettner A, Mohle F, Roider J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol. 2010;248:819-824.
20. Thumann G, Stöcker M, Maltusch C, et al. High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther. 2010;17:181-189.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
22. Leung KW, Liu M, Xu X, Seiler MJ, Barnstable CJ, Tombran-Tink J. Expression of ZnT and ZIP zinc transporters in the human RPE and their regulation by neurotrophic factors. Invest Ophthalmol Vis Sci. 2008;49:1221-1231.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods. 2001;25:402-408.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
25. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 1998;143:1341-1352.
26. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International. 2004;11:36-42.
27. Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem. 2006;39:267-276.
28. Ohno-Matsui K, Hirose A, Yamamoto S, et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol. 2002;160:711-719.
29. Ohno-Matsui K. [Molecular mechanism for choroidal neovascularization in age-related macular degeneration]. Nippon Ganka Gakkai Zasshi. 2003;107:657-673.
30. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008;12:iii-201.
31. Coleman HR, Chan CC, Ferris 3rd FL, Chew EY. Age-related macular degeneration. Lancet. 2008;372:1835-1845.
32. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293:1509-1513.
33. Semkova I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci U S A. 2002;99:13090-13095.
34. Kumar-Singh R, Farber DB. Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration. Hum Mol Genet. 1998;7: 1893-1900.
35. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
36. Zhou XY, Liao Q, Pu YM, et al. Ultrasound-mediated microbubble delivery of pigment epithelium-derived factor gene into retina inhibits choroidal neovascularization. Chin Med J (Engl). 2009;122:2711-2717.
37. Ding XQ, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One. 2009;4:e7410.
38. Yoshioka Y, Abe T, Wakusawa R, et al. Recombinant AAV-transduced iris pigment epithelial cell transplantation may transfer vector to native RPE but suppress systemic dissemination. Invest Ophthalmol Vis Sci. 2006;47:745-752.
39. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008;19:463-474.
40. Broadhead ML, Becerra SP, Choong PF, Dass CR. The applied biochemistry of PEDF and implications for tissue homeostasis. Growth Factors. 2010.
41. Bilak MM, Becerra SP, Vincent AM, Moss BH, Aymerich MS, Kuncl RW. Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci. 2002;22:9378-9386.
42. DeCoster MA, Schabelman E, Tombran-Tink J, Bazan NG. Neuroprotection by pigment epithelial-derived factor against glutamate toxicity in developing primary hippocampal neurons. J Neurosci Res. 1999;56:604-610.
43. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
44. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med. 2002;8:330-334.
45. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med. 2006;12:497-502.
46. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther. 2004;11:325-332.